HFHenrik Ten Freyhaus

Henrik Ten Freyhaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henrik Ten Freyhaus has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Echokardiographie in der Kardiologie – Basistool, aktuelle Entwicklungen und Zukunftsaussichten

    by Henrik Ten Freyhaus, Sebastian Kruck

    Zusammenfassung Die transthorakale Echokardiographie bleibt trotz der Fortschritte in der Computertomographie und Magnetresonanztomographie das zentrale bildgebende Verfahren in Kardiologie und Innerer Medizin. Ihre Stärken liegen in ubiquitärer Verfügbarkeit, Wiederholbarkeit und direkter Verknüpfung von Befund und Symptomatik. Im Alltag beantwortet sie therapierelevante Fragen in Bezug auf Pumpfunktion, Perikarderguss oder Tamponade, relevante Klappenerkrankungen, Herzinsuffizienz mit erhaltener Ejektionsfraktion, pulmonale Hypertonie sowie das hämodynamische Profil bei Schock, Sepsis oder Kreislaufinstabilität. Voraussetzung für eine belastbare Diagnostik ist die standardisierte Untersuchung gemäß Leitlinien. Bei Klappenerkrankungen geht es nicht nur um Detektion, sondern um die präzise Quantifizierung der Vitien und die Einschätzung ihrer Dringlichkeit. Dies gilt besonders für anspruchsvolle Konstellationen wie die häufig unterschätzte Low-flow-low-gradient-Aortenklappenstenose. Im Akutsetting kann die fokussierte kardiale Sonographie rasch Orientierung geben, ersetzt jedoch nicht die vollständige transthorakale Untersuchung. Grenzen der Methode liegen weniger im Verfahren selbst als in unzureichender Standardisierung, Fehlanwendung und eingeschränkter Bildqualität. Aktuelle und künftige Entwicklungen werden die Aussagekraft weiter erhöhen. Beispiele sind hier die durch künstliche Intelligenz gestützte Auswertung mit automatisierter Analyse verschiedener Parameter, die Mustererkennung zur Krankheitsdetektion, „speckle tracking strain“ und zugehörige Weiterentwicklungen, linksatrialer Strain zur erweiterten Beurteilung der diastolischen Funktion, 3D-Echokardiographie sowie „shear wave imaging“ zur Abschätzung myokardialer Steifigkeit. Damit bleibt die Echokardiographie ein unverzichtbares, dynamisches und effektives Verfahren. Entscheidend sind standardisierte Abläufe, leitliniengerechte Quantifizierung und die Einordnung der Befunde in den klinischen Kontext.

  • Open Access

    How can common errors in left heart echocardiography be avoided? An expert proposalby the German Working Group of Cardiovascular Ultrasound

    by Andreas Hagendorff, Stephan Stöbe, Andreas Helfen, Fabian Knebel, Ertunc Altiok, Wolfgang Fehske, Tarek Bekfani, Ole-A. Breithardt, Aydan Ewers, Ali Hamadanchi, et al.

    Echocardiography is the most commonly used imaging modality in cardiology and serves as a crucial first step in diagnosis and therapeutic decision making. This expert proposal aims to address methodological requirements in order to make the correct diagnosis and prevent diagnoses from being overlooked due to improper use. Graphical Abstract

  • Open Access

    Endomyocardial biopsy in patients with myocarditis—still justified in the CMR era? A single-centre experience

    by Katharina Seuthe, Roman Pfister, Lenhard Pennig, Ute Mons, Karin Klingel, Henrik Ten Freyhaus

    Background: In the past decades, cardiovascular magnetic resonance (CMR) was established as a non-invasive tool supporting the diagnosis of myocarditis and there is often reluctance in performing EMB due to potentially severe complications. We sought to identify patient subgroups that could still benefit from EMB in the CMR era. Methods: Data of patients presenting with myocarditis between 01/2016 and 06/2023 were analysed according to patient risks. Prespecified risk factors were (i) left ventricular ejection fraction (LVEF) ≤ 30%; (ii) severe arrhythmias; or (iii) pre-existing autoimmune disease. Furthermore, the subgroup of recurrent myocarditis cases was analysed separately. Results: A total of 137 patients (35.5 ± 14.8 years, 80.3% male) were included. 26/137 patients had a documented LVEF ≤ 30%, 13/137 a LVEF > 30% with at least one other risk factor and 98/137 a LVEF > 30% without risk factors. EMB was performed in 21/26 patients with LVEF ≤ 30% (80.8%), in 7/13 patients with LVEF > 30% and risk factors (53.8%) and in 16/98 (16%) patients without risk factors. EMB led to the initiation of immunosuppressive therapy in 11/28 patients with risk factors (39.3%) and in none of the patients without risk factors (0/16, 0%, p = 0.003). With respect to the subgroup of patients presenting with recurrent myocarditis ( n = 10), no specific therapy was initiated. Conclusions: Due to a high therapeutic yield for initiation of immunosuppressive therapy in non-infectious myocarditis, performing EMB should be considered in all high-risk patients. In patients without clinical risk factors including cases of recurrent or relapsing myocarditis no specific therapy was initiated.


  • Open Access

    Echocardiographic assessment of left atrial appendage morphology and function—an expert proposal by the German Working Group of Cardiovascular Ultrasound

    by Andreas Hagendorff, Stephan Stöbe, Andreas Helfen, Fabian Knebel, Ertunc Altiok, Stephan Beckmann, Tarek Bekfani, Thomas Binder, Aydan Ewers, Ali Hamadanchi, et al.

    The left atrial appendage is a blind ending cardiac structure prone to blood stasis due to its morphology. This structure is a preferred region of thrombogenesis in relation to reduced myocardial contractility of the atrial wall. Blood stasis occurs primarily in low flow conditions. One of the tasks of echocardiography is the analysis of morphology and function of the left atrial appendage. The detection of thrombi by echocardiography is difficult and must be carried out thoroughly and carefully to avoid potential complications—especially in the context of rhythm control. The assessment of thromboembolic risk, especially in patients with unknown and presumed atrial fibrillation is a second challenge by characterizing atrial function and flow conditions in the left atrial appendage. Thus, this proposal focuses on the obvious problems of echocardiography when assessing left atrial appendage and the role of this method in planning a potential interventional closure of left atrial appendage.


  • Open Access

    Echocardiographic assessment of atrial, ventricular, and valvular function in patients with atrial fibrillation—an expert proposal by the german working group of cardiovascular ultrasound

    by Andreas Hagendorff, Stephan Stöbe, Andreas Helfen, Fabian Knebel, Ertunc Altiok, Stephan Beckmann, Tarek Bekfani, Thomas Binder, Aydan Ewers, Ali Hamadanchi, et al.

    Echocardiography in patients with atrial fibrillation is challenging due to the varying heart rate. Thus, the topic of this expert proposal focuses on an obvious gap in the current recommendations about diagnosis and treatment of atrial fibrillation (AF)—the peculiarities and difficulties of echocardiographic imaging. The assessment of systolic and diastolic function—especially in combination with valvular heart diseases—by echocardiography can basically be done by averaging the results of echocardiographic measurements of the respective parameters or by the index beat approach, which uses a representative cardiac cycle for measurement. Therefore, a distinction must be made between the functionally relevant status, which is characterized by the averaging method, and the best possible hemodynamic status, which is achieved with the most optimal left ventricular (LV) filling according to the index beat method with longer previous RR intervals. This proposal focuses on left atrial and left ventricular function and deliberately excludes problems of echocardiography when assessing left atrial appendage in terms of its complexity. Echocardiography of the left atrial appendage is therefore reserved for its own expert proposal.


  • Open Access

    Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment

    by Svenja Ney, Roman Johannes Gertz, Lenhard Pennig, Richard J. Nies, Udo Holtick, Linus A. Völker, Gilbert Wunderlich, Katharina Seuthe, Christopher Hohmann, Clemens Metze, et al.

    Background: Recently, a disease modifying therapy has become available for transthyretin amyloid cardiomyopathy (ATTR-CM). A validated monitoring concept of treatment is lacking, but a current expert consensus recommends three clinical domains (clinical, biomarker and ECG/imaging) assessed by several measurable features to define disease progression. Methods: We retrospectively analyzed data of wild-type ATTR-CM patients initiating tafamidis therapy assessed within our local routine protocol at baseline and 6-months follow-up with respect to the frequency of values beyond the proposed thresholds defining disease progression. Additionally, associations of cardiac magnetic resonance (CMR) tomography with clinical domains were examined within a subgroup. Results: Sixty-two ATTR-CM patients were included (88.7% male, mean age 79 years). In total, 16.1% of patients had progress in the clinical and functional domain, 33.9% in the biomarker domain and 43.5% in the imaging/electrocardiography (ECG) domain, with the latter driven by deterioration of the diastolic dysfunction grade and global longitudinal strain. In total, 35.5% of patients showed progress in none, 35.5% in one, 29.0% in two and no patient in three domains, the latter indicating overall disease progression. A subgroup analysis of twenty-two patients with available baseline and follow-up CMR data revealed an increase in CMR-based extracellular volume by more than 5% in 18.2% of patients, with no significant correlation with progress in one of the clinical domains. Conclusions: We provide first frequency estimates of the markers of disease progression according to a recent expert consensus statement, which might help refine the multiparametric monitoring concept in patients with ATTR-CM.


  • Bildgebung und apparative Untersuchung

    by Sebastian Maier, Jan Becher, Insa Emrich, Felix Mahfoud, Marcus Koller, Noureddin Sawan, Michael Gramlich, Caroline Morbach, Henrik Ten Freyhaus, Jörg Strotmann, et al.

  • Cardiac Manifestations in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Single-Center Study

    by Sita Arjune, Franziska Grundmann, Polina Todorova, Claudia Hendrix, Roman Pfister, Henrik Ten Freyhaus, Roman-Ulrich Müller

    Key Points: Cardiovascular disease—a key driver of morbidity in CKD—is common in patients with autosomal dominant polycystic kidney disease (ADPKD). Pathologic echocardiography findings, including valvular defects, aortic root dilation, and hypertrophy, are found in most patients with ADPKD. These findings correlate with parameters indicating disease progression in ADPKD. Echocardiography should be offered to all patients with ADPKD. Background: ADPKD is the most common monogenetic kidney disease and results in kidney failure in >75% of affected individuals. As a systemic disorder, ADPKD is associated with a variety of extrarenal manifestations, including cardiac manifestations, that affect the majority of patients. We characterized the cardiac involvement in patients with ADPKD from the German AD(H)PKD registry and compared them with kidney donor candidates as controls. Methods: In this single-center cohort study, we evaluated 141 patients with ADPKD (44.17±11.23 years) from the German AD(H)PKD registry and 60 kidney donor candidates (55.08±10.21 years). All patients underwent clinical examination, abdominal MRI, and transthoracic echocardiography. Results: Of the patients with ADPKD, 65% showed hypertrophy of the left ventricle (as defined by an end-diastolic interventricular septal wall thickness [IVSd] >10 mm) compared with 55% in control patients. Mitral regurgitation was the most common finding among 54% of patients with ADPKD who exhibited valvular dysfunction, albeit mild in most patients. Interestingly, left ventricular ejection fraction (LV-EF) differed significantly between both groups, with higher values in patients with ADPKD (64%±6% versus 60%±6%), whereas other parameters, including IVSd, left ventricular end-diastolic diameter (LVEDD), tricuspid annular plane systolic excursion (TAPSE), and pressure gradients across the aortic and tricuspid valve were similar between groups. Correlations of echocardiographic parameters with markers of disease progression revealed statistically significant associations for aortic root diameter (P=0.01), the pressure gradient across the aortic valve (AV dPmax; P=0.0003), and IVSd (P=0.0001), indicating rapid kidney disease progression may also be associated with cardiac findings. Conclusion: Cardiovascular abnormalities are prevalent in patients with ADPKD. Considering the importance of cardiovascular disease for outcomes in CKD, early management and possibly prevention are important goals of any treatment scheme. Consequently, echocardiography should be offered to all patients with ADPKD in routine management.


  • Open Access

    Prevalence of left ventricular thrombus formation after mitral valve edge-to-edge repair

    by Tobias Tichelbäcker, Maria Isabel Körber, Victor Mauri, Christos Iliadis, Clemens Metze, Christoph Adler, Stephan Baldus, Volker Rudolph, Marcel Halbach, Roman Pfister, et al.

    The prevalence of left ventricular (LV) thrombus formation following percutaneous mitral valve edge-to-edge repair (TMVR) with the MitraClip system is unclear. Decreased total stroke volume and perfusion of the LV apex after mitral valve repair may facilitate thrombus formation especially in the context of reduced LV function. LV thrombus may cause disabling stroke or other thromboembolic events in this elderly and multimorbid patient cohort. Analyses of the prevalence of and risk factors for left ventricular thrombus formation in patients treated with the MitraClip system due to severe mitral valve regurgitation. All discharge and follow-up transthoracic echocardiographic examinations up to 6 months of 453 consecutive patients treated with the MitraClip system were screened for the presence of LV thrombus. Prevalence of LV thrombus formation was 1.1% (5/453). Importantly, LV thrombi were exclusively found in patients with severely depressed left ventricular systolic function (LV-EF < 30%), comprising a prevalence of 4.4% in this subgroup (5/113). Importantly, two of these patients were under active DOAC therapy with Rivaroxaban and Apixaban, respectively. Apart from LV-EF, we did not identify other factors that might have facilitated LV thrombus formation. LV thrombus formation following percutaneous mitral valve repair occurred exclusively in patients with severely depressed LV-EF. As two patients developed LV thrombus despite of DOAC therapy, anticoagulation with a Vitamin K antagonist should be considered in patients with an indication for oral anticoagulation following TMVR.


  • Coagulation-independent effects of thrombin and Factor Xa: role of protease-activated receptors in pulmonary hypertension

    by Christine Joseph, Eva Maria Berghausen, Arnica Behringer, Bernhard Rauch, Henrik Ten Freyhaus, Leoni Luisa Gnatzy-Feik, Max Krause, Dickson W L Wong, Peter Boor, Stephan Baldus, et al.

    Pulmonary arterial hypertension (PAH) is a devastating disease with limited therapeutic options. Vascular remodelling of pulmonary arteries, characterized by increased proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs), is a hallmark of PAH. Here, we aimed to systematically characterize coagulation-independent effects of key coagulation proteases thrombin and Factor Xa (FXa) and their designated receptors, protease-activated receptor (PAR)-1 and -2, on PASMCs in vitro and experimental PAH in vivo. In human and murine PASMCs, both thrombin and FXa were identified as potent mitogens, and chemoattractants. FXa mediated its responses via PAR-1 and PAR-2, whereas thrombin signalled through PAR-1. Extracellular-signal regulated kinases 1/2, protein kinase B (AKT), and sphingosine kinase 1 were identified as downstream mediators of PAR-1 and PAR-2. Inhibition of FXa or thrombin blunted cellular responses in vitro, but unexpectedly failed to protect against hypoxia-induced PAH in vivo. However, pharmacological inhibition as well as genetic deficiency of both PAR-1 and PAR-2 significantly reduced vascular muscularization of small pulmonary arteries, diminished right ventricular systolic pressure, and right ventricular hypertrophy upon chronic hypoxia compared to wild-type controls. Our findings indicate a coagulation-independent pathogenic potential of thrombin and FXa for pulmonary vascular remodelling via acting through PAR-1 and PAR-2, respectively. While inhibition of single coagulation proteases was ineffective in preventing experimental PAH, our results propose a crucial role for PAR-1 and PAR-2 in its pathobiology, thus identifying PARs but not their dedicated activators FXa and thrombin as suitable targets for the treatment of PAH.